Antibody-based immunotherapy of solid cancers: Progress and possibilities

Immunotherapy

Volumn 7, Issue 8, 2015, Pages 923-939

  Nicodemus, Christopher F ^a  

^a AIT Strategies   (United States)

Author keywords

check point; IgE; IgG; ipilimumab; macrophage; monocyte; myeloid; nivolumab; oregovomab; PD 1; second signal; T cell; tumor stroma

Indexed keywords

CHEMOKINE; FC RECEPTOR; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CROSS PRESENTATION; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOREGULATION; NONHUMAN; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECTS; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; TRENDS; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84942163370     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.57     Document Type: Review

References (92)

1. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
3. Genentech. www.gene.com/media/product-information/herceptin
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
5. Lefranc MP, Lefranc G. The Immunoglobulin FactsBook. Academic Press, MA, USA (2001).
6. Nicodemus CF, Smith LM, Schultes BC. Role of monoclonal antibodies in tumor-specific immunity. Expert Opin. Biol. Ther. 7(3), 331-343 (2007).
7. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol. Immunother. 62(2), 217-223 (2013).
8. Weiner GJ. Rituximab: mechanism of action. Semin. Hematol. 47(2), 115-123 (2010).
9. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivoactivated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29(4), 388-397 (2006).
10. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3), 754-758 (2002).
11. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: A novel concept with promise for the treatment of cancer. MAbs 6(1), 54-72 (2014).
12. Nigro E, Siccardi A, Vangelista L. Role and redirection of IgE against cancer. Antibodies 2(2), 371-391 (2013).
13. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat. Rev. Immunol. 7(5), 365-378 (2007).
14. Edkins AL, Borland G, Acharya M, Cogdell RJ, Ozanne BW, Cushley W. Differential regulation of monocyte cytokine release byV and(2) integrins that bind CD23. Immunology 136(2), 241-251 (2012).
15. Paul WE. Fundamental Immunology (7th Edition). Lippincott Williams & Wilkins, PA, USA (2012).
16. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. (262), 3-11 (1991).
17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
18. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 3(9), 745-756 (2003).
19. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br. J. Haematol. 130(6), 809-824 (2005).
20. Guilliams M, Ginhoux F, Jakubzick C et al. Dendritic cells, monocytes and macrophages: A unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14(8), 571-578 (2014).
21. Muthuswamy R, Berk E, Junecko BF et al. NF-B hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 72(15), 3735-3743 (2012).
22. Innate Pharma. www.innate-pharma.com/en/product-pipeline
23. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010).
24. Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74(24), 7250-7259 (2014).
25. Platten M, Von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 5, 673 (2014).
26. Khazaie K, Blatner NR, Khan MW et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 30(1), 45-60 (2011).
27. Movahedi K, Laoui D, Gysemans C et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70(14), 5728-5739 (2010).
28. Lippitz BE. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 14(6), e218-e228 (2013).
29. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33(38), 4623-4631 (2014).
30. Tan W, Zhang W, Strasner A et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335), 548-553 (2011).
31. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20), 5498-5505 (2011).
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
33. Harbeck N, Beckmann MW, Rody A et al. HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer. Breast Care (Basel) 8(1), 49-55 (2013).
34. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010).
35. Kawakami H, Okamoto I, Yonesaka K et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 5(23), 11847-11856 (2014).
36. Price TJ, Peeters M, Kim TW et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wildtype KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority Phase 3 study. Lancet Oncol. 15(6), 569-579 (2014).
37. Wakui H, Yamamoto N, Nakamichi S et al. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73(3), 511-516 (2014).
38. Lorusso P, Janne PA, Oliveira M et al. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 19(11), 3078-3087 (2013).
39. Zhu AX, Gold PJ, El-Khoueiry AB et al. First-in-man Phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19(4), 920-928 (2013).
40. US FDA. www.fda.gov/newsevents/newsroom/pressannouncements
41. Ascierto PA. Is there still a role for tremelimumab in the treatment of cancer? Transl. Cancer Res. 2(1), 48-50 (2013).
42. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
43. Robert C, Ribas A, Wolchok JD et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a Phase 1 trial. Lancet 384(9948), 1109-1117 (2014).
44. Atkins MB, Kudchadkar RR, Sznol M et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. ASCO Meeting Abstracts 32(15 Suppl.), 9001 (2014).
45. NIH. Study NCT00729664. www.clinicaltrials.gov
46. NIH. Study NCT02174172. www.clinicaltrials.gov
47. Lutzky J, Antonia SJ, Blake-Haskins A et al. A Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 32(15 Suppl.), 3001 (2014).
48. NIH. Study NCT01772004. www.clinicaltrials.gov
49. Segal NH, Hodi FS, Sanborn RE et al. A Phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. ASCO Meeting Abstracts 32(15 Suppl.), TPS3115 (2014).
50. Goding SR, Wilson KA, Xie Y et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J. Immunol. 190(9), 4899-4909 (2013).
51. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006).
52. Yiu HH, Graham AL, Stengel RF. Dynamics of a cytokine storm. PLoS ONE 7(10), e45027 (2012).
53. Vitale LA, He LZ, Thomas LJ et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin. Cancer Res. 18(14), 3812-3821 (2012).
54. Kohrt HE, Godwin JE, Lossos IS et al. A Phase Ib, openlabel, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/ refractory B-cell malignancies. ASCO Meeting Abstracts 31(15 Suppl.), TPS3108 (2013).
55. Segal NH, Gopal AK, Bhatia S et al. A Phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. ASCO Meeting Abstracts 32(15 Suppl.), 3007 (2014).
56. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19(5), 1035-1043 (2013).
57. Beatty GL, Torigian DA, Chiorean EG et al. A Phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19(22), 6286-6295 (2013).
58. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
59. NIH. Study NCT02221960. www.clinicaltrials.gov
60. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
61. NIH. Study NCT01239134. www.clinicaltrials.gov
62. NIH. Study NCT02132754. www.clinicaltrials.gov
63. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
64. Thomas M, Kienast Y, Scheuer W et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared with Pan-Angiopoietin-1/-2 inhibitors. PLoS ONE 8(2), e54923 (2013).
65. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebocontrolled, Phase 3 trial. Lancet 383(9911), 31-39 (2014).
66. Braly P, Nicodemus CF, Chu C et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized Phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J. Immunother. 32(1), 54-65 (2009).
67. De Bono JS, Rha SY, Stephenson J et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. 15(12), 1825-1833 (2004).
68. Morris JC, Tan AR, Olencki TE et al. Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9(3), e90353 (2014).
69. Bijjiga E, Martino A. Interleukin 10 (IL-10) regulatory cytokine and its clinical consequences. J. Clin. Cell. Immunol. doi:10.4172/2155-9899.S1-007 (2013) (Epub ahead of print).
70. Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2(3), 194-199 (2014).
71. Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43(8), 1790-1800 (2000).
72. Lee DW, Gardner R, Porter DL et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2), 188-195 (2014).
73. Mollick J, Madiyalakan M, Nicodemus C. Muci specific IGE to modify myeloid derived cells of the tumor microenvironment. J. Immunother. Cancer 1(Suppl. 1), P245 (2013).
74. Teo PZ, Utz PJ, Mollick JA. Using the allergic immune system to target cancer: Activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol. Immunother. 61(12), 2295-2309 (2012).
75. Daniels-Wells TR, Helguera G, Leuchter RK et al. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer 13, 195 (2013).
76. Daniels TR, Leuchter RK, Quintero R et al. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol. Immunother. 61(7), 991-1003 (2012).
77. Karagiannis P, Singer J, Hunt J et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 58(6), 915-930 (2009).
78. Gould HJ, Mackay GA, Karagiannis SN et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 29(11), 3527-3537 (1999).
79. Jonker DJ, O'callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
80. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 37(5), 450-454 (2010).
81. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
82. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
83. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosinebased switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173(2), 945-954 (2004).
84. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
85. US FDA. www.fda.gov/newsevents/newsroom/pressannouncements
86. US FDA. www.fda.gov/newsevents
87. Snyder Charen A, Makarov V, Merghoub T et al. The neoantigen landscape underlying clinical response to ipilimumab. ASCO Meeting Abstracts 32(15 Suppl.), 3003 (2014).
88. Kefford R, Ribas A, Hamid O et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts 32(15 Suppl.), 3005 (2014).
89. Adaniel C, Rendleman J, Polsky D et al. Germline genetic determinants of immunotherapy response in metastatic melanoma. ASCO Meeting Abstracts 32(15 Suppl.), 3004 (2014).
90. Anderson AC. Tim-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2(5), 393-398 (2014).
91. Maus MV, Grupp SA, Porter DL, June CH. Antibodymodified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17), 2625-2635 (2014).
92. Nagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin. Cancer Res. 20(5), 1223-1234 (2014).